Immunic Launches Innovative Phase 2 Trial
Immunic, Inc. (Nasdaq: IMUX) has made a significant advancement in tackling the urgent health concern of Post COVID Syndrome (PCS) by announcing the enrollment of its first patient in an investigator-sponsored Phase 2 clinical trial. This important initiative is being led by distinguished researchers at a prominent academic institution, with the goal of examining the effects of Vidofludimus Calcium (IMU-838) on individuals experiencing the long-term repercussions of COVID-19.
Significance of the Clinical Trial
Post COVID Syndrome manifests through a variety of debilitating symptoms, with severe fatigue being the most prevalent. By participating in this trial, Immunic aims not only to alleviate the symptoms of PCS but also to investigate the potential involvement of Epstein-Barr Virus reactivation in causing these symptoms, especially fatigue. Previous studies have raised concerns about EBV reactivation as a possible contributor to fatigue in both PCS and multiple sclerosis (MS) patients.
Insights from Experts
Prof. Dr. Maria J.G.T. Vehreschild, the Principal Investigator for the RAPID_REVIVE trial, highlighted the urgent need for effective treatments for PCS and its associated fatigue. She noted that Vidofludimus Calcium has demonstrated promising antiviral and anti-inflammatory properties, making it a strong candidate for this trial.
Company Overview
Daniel Vitt, Ph.D., CEO of Immunic, expressed his pride in having Vidofludimus Calcium chosen for this important research project. The company is optimistic about the drug's potential to reduce fatigue, based on previous studies that suggest its effectiveness.
Trial Details and Objectives
The RAPID_REVIVE trial is a comprehensive randomized, placebo-controlled, double-blind study that aims to enroll 376 patients across various clinical sites. Immunic will provide the study medication, focusing on specific endpoints such as changes in physical function and mental health metrics throughout the trial.
About Vidofludimus Calcium
Vidofludimus Calcium is an innovative treatment currently undergoing multiple clinical trials, particularly for relapsing and progressive MS. As a selective immune modulator, its action on the neuroprotective transcription factor Nurr1 is linked to direct neuroprotective effects and potential antiviral benefits.
Looking Ahead
As the trial unfolds, Immunic anticipates collecting crucial data that could also inform their ongoing research into multiple sclerosis. The findings from this study may provide deeper insights into the relationship between EBV reactivation and fatigue, which could influence treatment strategies for MS patients as well.
Contact Information
For further details, please contact Immunic, Inc.:
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
[email protected]
Frequently Asked Questions
What is the purpose of the RAPID_REVIVE trial?
The trial aims to evaluate the effectiveness of Vidofludimus Calcium in treating Post COVID Syndrome, particularly focusing on its effects on fatigue and physical function.
Who is leading the clinical trial?
The clinical trial is being led by Prof. Dr. Maria J.G.T. Vehreschild from the University Hospital Frankfurt.
How many patients will be enrolled in the trial?
The study is set to enroll 376 patients across 11 clinical sites.
What is Vidofludimus Calcium?
Vidofludimus Calcium is an investigational medication aimed at treating chronic inflammatory and autoimmune diseases, including multiple sclerosis and Post COVID Syndrome.
What outcomes are expected from this trial?
The study will assess changes in both physical and mental health, as well as fatigue levels in patients over a defined period.
